Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr Kim Chi, a medical oncologist and the Chief Medical Officer of BC Cancer. The award is presented yearly at the Annual Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
The CCTG Phase III Team Award for Intergroup-Led Trials was presented to the CO29 Team BCCA from Vancouver Cancer Centre and the Annual Spring Meeting. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance.
Dr. Courtney Coschi was recognized with the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting. The award is presented to a new investigator who has worked at the CCTG Central Office, IND projects, or has contributed significantly to the conduct of an IND trial at a member centre.
Congrats to the MA39 clinical trials team at Tom Baker Cancer Centre in Calgary for receiving the ,Phase III Team Award for CCTG-Led Trials at a ceremony recently held at the Annual Spring Meeting in Toronto. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance
Congratulations to the PR19 Team from the Odette Cancer Centre at Sunnybrook for being recognized with the Phase III Team Award for CCTG-Led Trials.
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr. Jolie Ringash, a radiation oncologist at the University of Toronto. The award is presented yearly at the Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.
